Robert Duggan Leading Innovation

Having successfully Pioneered Robotic Surgery, Robert "Bob" Duggan Is Giving Hope to Cancer Patients Through His Innovative Biotech Company

SUNNYVALE, Calif., May 7, 2014 /PRNewswire-iReach/ -- Robert Duggan is at it again, this time leading the way with innovation in the field of cancer treatment. Duggan is CEO of Pharmacyclics Inc., a biotech company based in Sunnyvale, California. He and his team are experiencing major success in treating patients with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL), two types of blood cancer, with their new drug,ibrutinib (brand name Imbruvica).

Photo -

Based on statistically significant clinical trial results, ibrutinib was assigned "breakthrough therapy" status by the FDA and has gained FDA approvals for treatment of MCL and CLL for patients who have received at least one prior therapy. Now patients suffering from either of these deadly forms of cancer have a promising new treatment option.

Robert Duggan and the team at Pharmacyclics have the objective of creating medicines that improve both the quality and duration of patients' lives. Achieving this objective requires hard work, sacrifice, money, organization, communication, affinity for what they do and a willingness to be of service to others.

Pharmacyclics was founded in 1991 and has approximately 500 employees. Last year alone, the company invested more than $54 million in research and development. Robert Duggan became CEO in 2008 and since that time, the company's share price and renown has increased exponentially.

Previously, Duggan was a pioneer in the field of robotic surgery. His former company, Computer Motion, performed the world's first FDA-approved robotics-assisted surgery in 1994. Subsequently, further developing these procedures, a surgeon manipulated robotic instruments in New York and removed a patient's gallbladder using robotic instruments in a hospital operating room in Strasbourg, France. Mr. Duggan was the co-creator of this project, which took place on September 7, 2001.

For his work in robotic surgery, Robert Duggan received "La Legion D'Honneur" from Jacques Chirac, the President of France at the time. The award recognizes Duggan for the introduction of robotic surgical technology to the French health care system and its significant impact on reducing patient trauma, reducing patient recovery time, and reducing health care cost.

Robert Duggan served as CEO and Chairman of the Board at Computer Motion from 1997 until the conclusion of its merger with Intuitive Surgical in June of 2003.

Robert Duggan, or Bob as he is better known, has not just been a leader in medical innovation, but also a leader in philanthropy. An important part of his success is his desire to work for the greater good, and to have an impact through giving.

Bob and his wife, Trish are leading supporters of social programs that are shown to positively influence the lives of millions of people worldwide. Reducing crime rates, preventing harmful drug and alcohol addiction, increasing literacy and many other worthwhile projects benefit from their support. In addition, the Duggans have been very supportive of the arts as well as their former university, UC Santa Barbara.

Robert Duggan continues to push forward in the area of medical innovation. Research and development is ongoing, as are Pharmacyclics' applications for additional FDA approvals. The future now looks brighter for blood cancer patients.  And, while Bob is no longer directly involved, the field of robotic surgery continues to grow and benefit patients worldwide.

Media Contact: Craig Edward, (323) 577-9325,

News distributed by PR Newswire iReach:

SOURCE  Communication Services



Books, Publishing & Information Services, Biotechnology, Health Care & Hospitals, New Products & Services

Need Help